2025
Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis
Klotz L, Smolders J, Lehto J, Matilainen M, Lütje L, Buchholz L, Albrecht S, Walter C, Varghese J, Wiendl H, Nylund M, Thomas C, Gardberg M, van den Bosch A, Airas L, Huitinga I, Kuhlmann T. Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nature Medicine 2025, 31: 2016-2026. PMID: 40301560, PMCID: PMC12176629, DOI: 10.1038/s41591-025-03625-7.Peer-Reviewed Original ResearchConceptsDisease progressionMultiple sclerosisRim lesionsLesion typeInnate immune activationCurrent multiple sclerosisPositron emission tomography studiesInflammatory cytokine productionEmission tomography studiesRelapse activityPatient selectionImmune activationIntrinsic inflammationCytokine productionRapid progressionMS progressionMS lesion typesImaging biomarkersLesionsUnfolded protein responseTranscriptional signatureDiseaseTomography studiesProtein responseCell rimMicroglia positron emission tomography and progression in multiple sclerosis: thalamus on fire
Zeydan B, Neyal N, Son J, Schwarz C, Thomas J, Morrison H, Bush M, Reid R, Przybelski S, Fought A, Jack C, Petersen R, Kantarci K, Lowe V, Airas L, Kantarci O. Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire. Brain Communications 2025, 7: fcaf141. PMID: 40322777, PMCID: PMC12046125, DOI: 10.1093/braincomms/fcaf141.Peer-Reviewed Original ResearchProgressive multiple sclerosisRelapsing multiple sclerosisPET uptakeMultiple sclerosisThalamic lesionsMicroglia densityMean diffusivityPaced Auditory Serial Addition Test scoresMultiple Sclerosis Functional Composite scoreClinical disease severityNeurite density indexBiomarkers of progressionAssociated with imaging biomarkersPositron emission tomographyGlobal disease burdenTranslocator protein PETOrientation dispersion indexDisease characteristicsPatientsEfficacy evaluationImaging biomarkersCorpus callosumEmission tomographyDisease severityThalamusQuinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-controlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse eventsA composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, Solnes L, Abramson V, Carey L, Rimawi M, Specht J, Storniolo A, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff A, Wahl R, Huang C, Stearns V, Thompson E, Connolly R. A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). The Breast 2025, 81: 104432. PMID: 40049115, PMCID: PMC11928837, DOI: 10.1016/j.breast.2025.104432.Peer-Reviewed Original ResearchTissue-based biomarkersBreast cancerHER2-positive breast cancerHER2 3+Negative predictive valueEarly metabolic changesNeoadjuvant pertuzumabScore cut-offNeoadjuvant therapyIntrinsic subtypesSULmaxC1D15PET/CTDays post-initiationHER2 proteinYouden indexComposite biomarkerDe-intensificationHER2Post-initiationPredictive valueBiomarker performanceC-statisticImaging biomarkersMetabolic changesReliability of Central Vein Sign Imaging With 3T FLAIR* in a Multicenter Study
Martin M, Cao Q, Luskin E, Renner B, Daboul L, O'Donnell C, Rodrigues P, Derbyshire J, Azevedo C, Bar‐Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prchkovska V, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Reich D, Ontaneda D, Shinohara R, Sati P. Reliability of Central Vein Sign Imaging With 3T FLAIR* in a Multicenter Study. Journal Of Neuroimaging 2025, 35: e70011. PMID: 39838609, DOI: 10.1111/jon.70011.Peer-Reviewed Original ResearchConceptsCentral vein signMulticenter studyMultiple sclerosisT2-weighted fluid-attenuated inversion recoveryClinical settingMRI vendorsFluid-attenuated inversion recoveryDiagnosis of MSPost-GdContrast-to-noise ratioGd-based contrast agentsNo significant differenceT2*-weightedImaging sitesDiagnostic imaging biomarkersImaging biomarkersInversion recoverySignificant differenceMRIFLAIRContrast agents
2024
Positron emission tomography an imaging biomarker in pulmonary fibrosis: from therapeutic mechanism to treatment monitoring
Cho S, Herzog E, Thorn S, Sinusas A. Positron emission tomography an imaging biomarker in pulmonary fibrosis: from therapeutic mechanism to treatment monitoring. EBioMedicine 2024, 111: 105519. PMID: 39700895, PMCID: PMC11718319, DOI: 10.1016/j.ebiom.2024.105519.Peer-Reviewed Original ResearchMolecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma
Santana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F, Coman D, Chapiro J. Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma. JHEP Reports 2024, 7: 101294. PMID: 40028344, PMCID: PMC11870164, DOI: 10.1016/j.jhepr.2024.101294.Peer-Reviewed Original ResearchT cell infiltrationHepatocellular carcinomaRadiological-pathological correlationImaging mass cytometryImmune responseT1-weighted MRITumor-infiltrating CD8+ T lymphocytesAnti-tumor immune responseCD8+ T lymphocytesIncreased T lymphocyte infiltrationImaging biomarkersNon-immunogenic tumorsSystemic lymph nodesT lymphocyte infiltrationMurine tumor modelsImmune cell typesLocal tumor therapyPrimary liver cancerNon-invasive imaging biomarkerTesla MRI scannerInduce liver cirrhosisImmunogenic tumorsLocoregional therapySystemic immunotherapyHCC lesionsRADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING
Zhu J, Hager T, Chadha S, Sritharan D, Weiss D, Hossain S, Osenberg K, Moore N, Aneja S. RADT-12. DERIVING IMAGING BIOMARKERS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING DEEP LEARNING. Neuro-Oncology 2024, 26: viii74-viii74. PMCID: PMC11553274, DOI: 10.1093/neuonc/noae165.0296.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaWhole-brain radiotherapyTreated with chemotherapyOverall survivalHigh-risk groupPatient phenotypesCentral nervous system lymphomaPCNSL treatmentRisk of neurocognitive side effectsImaging biomarkersC-statisticOne-year OSTwo-year OSNervous system lymphomaAssociated with improved outcomesLog-rank testNeurocognitive side effectsTime-dependent AUCBrain radiotherapySystem lymphomaTumor volumeTumor sizeRisk stratificationAnalyses assessed differencesSub-analysisRadiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation
Beddok A, Orlhac F, Rozenblum L, Calugaru V, Créhange G, Dercle L, Nioche C, Thariat J, Marin T, El Fakhri G, Buvat I. Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie 2024, 28: 597-602. PMID: 39406602, DOI: 10.1016/j.canrad.2024.09.002.Peer-Reviewed Original ResearchPersonalized radiotherapyTumor localizationTreatment planningMedian AUCImaging modalitiesRisk of recurrenceHead and neckImprove treatment precisionPredicting clinical outcomesOptimal treatment planQuantitative imaging biomarkersRecurrent tumorsApplication of radiomicsRecurrent cancerClinical radiotherapyExternal validationClinical outcomesRadiotherapyReirradiationLack of external validationMEDLINE searchTreatment precisionImaging biomarkersImaging protocolTumorPhenotypic Characterization of Patients with ADPKD with PKD1 and PKD2 Pathogenic Variants Using Advanced Imaging Biomarkers
Borghol A, Debeh F, Ghanem A, Paul S, Alkhatib B, Nader N, Gregory A, Yang H, Hanna C, Dahl N, Kline T, Harris P, Chebib F. Phenotypic Characterization of Patients with ADPKD with PKD1 and PKD2 Pathogenic Variants Using Advanced Imaging Biomarkers. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024jkdywd8g. DOI: 10.1681/asn.2024jkdywd8g.Peer-Reviewed Original ResearchMulticenter Automated Central Vein Sign Detection Performs as Well as Manual Assessment for the Diagnosis of Multiple Sclerosis.
Manning A, Letchuman V, Martin M, Gombos E, Robert-Fitzgerald T, Cao Q, Raza P, O'Donnell C, Renner B, Daboul L, Rodrigues P, Ramos M, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Suthiphosuwan S, Schindler M, Bilello M, Song J, Sotirchos E, Sicotte N, Al-Louzi O, Solomon A, Reich D, Ontaneda D, Sati P, Shinohara R. Multicenter Automated Central Vein Sign Detection Performs as Well as Manual Assessment for the Diagnosis of Multiple Sclerosis. American Journal Of Neuroradiology 2024, 46: 620-626. PMID: 39332906, PMCID: PMC11979820, DOI: 10.3174/ajnr.a8510.Peer-Reviewed Original ResearchCentral vein signCVS+ lesionsWhite matter lesionsMultiple sclerosisMulticenter studyProportions of white matter lesionsSuspicion of MSReceiver-operating characteristic curveFluid-attenuated inversion recoveryDiagnosis of multiple sclerosisDiagnosis of MSMagnetic resonance imagingAtypical clinical syndromeRadiological mimicsClinical syndromeDiagnostic imaging biomarkersManual assessmentT MRIClinical implementationImaging biomarkersLesionsInversion recoveryResonance imagingCharacteristic curveInter-rater reliabilityMisdiagnosis of Multiple Sclerosis: Past, Present, and Future
Rjeily N, Solomon A. Misdiagnosis of Multiple Sclerosis: Past, Present, and Future. Current Neurology And Neuroscience Reports 2024, 24: 547-557. PMID: 39243340, DOI: 10.1007/s11910-024-01371-w.Peer-Reviewed Original ResearchMS diagnostic criteriaMultiple sclerosisDiagnostic criteriaCentral vein signParamagnetic rim lesionsAssociated with misdiagnosisRecent FindingsRecent studiesMS misdiagnosisMRI findingsEvaluating patientsSuspected MSDiagnostic accuracyRim lesionsFindingsRecent studiesImaging biomarkersMisdiagnosisDiagnostic biomarkersCommon disordersPatientsBiomarkersPotential strategyDiagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis
Toljan K, Daboul L, Raza P, Martin M, Cao Q, O’Donnell C, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis. Multiple Sclerosis Journal 2024, 30: 1268-1277. PMID: 39234802, PMCID: PMC11421977, DOI: 10.1177/13524585241271988.Peer-Reviewed Original ResearchConceptsCentral vein signPositive predictive valueOligoclonal bandsDiagnostic performanceMS diagnosisCerebrospinal fluidMultiple sclerosisPredictive valueNegative predictive valueCerebrospinal fluid testingRadiological suspicionDiagnostic accuracyImaging biomarkersDiagnosisDiagnostic biomarkersMonthsSclerosisBiomarkersPilot studyBaselineSelection 3Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
Matthews D, Kinney J, Ritter A, Andrews R, Strom E, Lukic A, Koenig L, Revta C, Fillit H, Zhong K, Tousi B, Leverenz J, Feldman H, Cummings J. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12490. PMID: 38988416, PMCID: PMC11233274, DOI: 10.1002/trc2.12490.Peer-Reviewed Original ResearchFluorodeoxyglucose positron emission tomographyGlial fibrillary acidic proteinPositron emission tomographyMagnetic resonance imagingPlasma biomarkersVolumetric magnetic resonance imagingMild to moderate ADFDG positron emission tomographyPhase 2 clinical trialNeurofilament light chainGlial fibrillary acidic protein concentrationFibrillary acidic proteinInflammation-related proteinsTemporal cortexLeft inferior temporal cortexModerate ADCognitive endpointsFluorodeoxyglucosePET uptakeInflammation biomarkersBaseline MMSEMild-to-moderate Alzheimer's disease patientsImaging biomarkersBiomarker heterogeneityEmission tomographyO-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results
Pellicer A, Taylor H, Alberich-Bayaari Á, Liu Y, Gamborg M, Barletta K, Heiser P, Pinton P, Bagger Y. O-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results. Human Reproduction 2024, 39: deae108.021. DOI: 10.1093/humrep/deae108.021.Peer-Reviewed Original ResearchDeep infiltrating endometriosisMagnetic resonance imagingVaginal ringLesion regressionImaging biomarkersLesion sizeAdverse eventsFractional volume of extravascular extracellular spaceAssociated with chronic pelvic painPlacebo-controlled phase 2 trialAdvanced stages of endometriosisVolume of extravascular extracellular spaceDopamine D2 receptor agonistLesion burdenTreatment efficacyGroup compared to placeboSeverity of adverse eventsDIE groupPlacebo vaginal ringChronic pelvic painD2 receptor agonistLesion typePhase 2 trialStages of endometriosisCompared to placeboNoninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1
Mannes P, Adams T, Farsijani S, Barnes C, Latoche J, Day K, Nedrow J, Ahangari F, Kaminski N, Lee J, Tavakoli S. Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1. Science Advances 2024, 10: eadm9817. PMID: 38896611, PMCID: PMC11186491, DOI: 10.1126/sciadv.adm9817.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseRisk stratificationMurine modelLung fibrosisLung diseaseModel of bleomycin-induced lung fibrosisBleomycin-induced lung fibrosisImaging biomarkersMurine model of bleomycin-induced lung fibrosisBronchoalveolar lavage cellsMonocyte-derived macrophagesPositron emission tomographyInflammatory endotypesPulmonary fibrosisLavage cellsPoor survivalNoninvasive assessmentTherapeutic monitoringEmission tomographyCMKLR1FibrosisClinical trajectoryLungLung regionsEvaluation of automated airway morphological quantification for assessing fibrosing lung disease
Pakzad A, Cheung W, Van Moorsel C, Quan K, Mogulkoc N, Bartholmai B, Van Es H, Ezircan A, Van Beek F, Veltkamp M, Karwoski R, Peikert T, Clay R, Foley F, Braun C, Savas R, Sudre C, Doel T, Alexander D, Wijeratne P, Hawkes D, Hu Y, Hurst J, Jacob J. Evaluation of automated airway morphological quantification for assessing fibrosing lung disease. Computer Methods In Biomechanics And Biomedical Engineering Imaging & Visualization 2024, 12: 2325361. DOI: 10.1080/21681163.2024.2325361.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis patientsDisease extentAbnormal airway dilatationCompared to healthy controlsFibrosing lung diseaseAirway segmentsVolumetric computed tomographyChest CTTraction bronchiectasisAirway dilationAirway measurementsLower lobePulmonary fibrosisAirway abnormalitiesLung diseaseHealthy controlsAirwayCT imagesImaging biomarkersClinical interpretationAirway branchingAutomated quantificationPatientsHealthy participantsAutomated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics
Gross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 34: 5056-5065. PMID: 38217704, PMCID: PMC11245591, DOI: 10.1007/s00330-023-10495-5.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiomics feature extractionLiver volumetryIntraclass correlation coefficientRadiomic featuresLiver segmentationAutomated liver volumetryHepatocellular carcinoma patientsMann-Whitney U testAutomated liver segmentationManual segmentationQuantitative imaging biomarkersCarcinoma patientsRetrospective studyInstitutional databaseAnatomical localizationClinical relevanceManual volumetryMann-WhitneyU testExternal validationInternal test setImaging biomarkersInclusion criteriaResultsIn totalThe diagnostic value of the central vein sign in radiologically isolated syndrome
Landes‐Chateau C, Levraut M, Okuda D, Themelin A, Cohen M, Kantarci O, Siva A, Pelletier D, Mondot L, Lebrun‐Frenay C, Lebrun‐Frenay C, Kantarci O, Siva A, Pelletier D, Azevedo C, Makhani N, Okuda D. The diagnostic value of the central vein sign in radiologically isolated syndrome. Annals Of Clinical And Translational Neurology 2024, 11: 662-672. PMID: 38186317, PMCID: PMC10963291, DOI: 10.1002/acn3.51986.Peer-Reviewed Original ResearchConceptsRadiologically isolated syndromeCentral vein signCVS+ lesionsNon-MSMultiple sclerosisControl group of sex-RIS diagnosisAge-matched subjectsDetectable preclinical phaseProportion of lesionsWhite matter lesionsGroup of sex-Effective imaging biomarkerMagnetic resonance imagingDiagnostic performanceDiagnostic accuracyDiagnostic valueLesion criteriaImaging biomarkersLesionsResonance imagingLesion-specificAbsolute numberControl groupROC comparisons
2023
Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas
Tillmanns N, Lost J, Tabor J, Vasandani S, Vetsa S, Marianayagam N, Yalcin K, Erson-Omay E, von Reppert M, Jekel L, Merkaj S, Ramakrishnan D, Avesta A, de Oliveira Santo I, Jin L, Huttner A, Bousabarah K, Ikuta I, Lin M, Aneja S, Turowski B, Aboian M, Moliterno J. Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas. Scientific Reports 2023, 13: 22942. PMID: 38135704, PMCID: PMC10746716, DOI: 10.1038/s41598-023-48918-4.Peer-Reviewed Original ResearchConceptsInformatics platformDeep learning algorithmsImaging featuresCDKN2A alterationsLearning algorithmHeterozygous lossHomozygous deletionLarge datasetsDeep white matter invasionGBM molecular subtypesNew informaticsQualitative imaging biomarkersWhole-exome sequencingQualitative imaging featuresGBM resectionRadiographic evidenceWorse prognosisPACSMolecular subtypesPial invasionImaging biomarkersCDKN2A mutationsAllele statusNoninvasive identificationMagnetic resonance images
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply